| Arformoterol tartrate Pharmacology |
| Arformoterol tartrate |
| About Arformoterol tartrate |
| Long acting beta-adrenoceptor agonist |
| Mechanism of Action of Arformoterol tartrate |
| Brovana is a selective beta2-adrenergic bronchodilator. Beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle. They cause stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. |
| Pharmacokinets of Arformoterol tartrate |
| Distribution:Protein binding- 52-65% Metabolism:Hepatic Elimination:Renal |
| Onset of Action for Arformoterol tartrate |
| N/A |
| Duration of Action for Arformoterol tartrate |
| N/A |
| Half Life of Arformoterol tartrate |
| 26 hours |
| Side Effects of Arformoterol tartrate |
| 1.Congestive heart failure 2.Cardiac arrhythmias 3.Agitation Cerebral infarction 4.Somnolence 5.Tremors 6.Skin rashes 7.Skin hypertrophy 8.Skin discolouration 9.Precipitation of herpes simplex or zoster infections 10.Glaucoma 11.Cystitis 12.Glycosuria 13.Hematuria 14.Gout 15.Leg cramps 16.Osteopenia 17.Exacerbation of collagen disorders. |
| Contra-indications of Arformoterol tartrate |
| Hypersensitivity. |
| Special Precautions while taking Arformoterol tartrate |
| 1.Long-acting beta-2 adrenergic agonists may increase the risk of asthma-related death 2.Renal and heaptic impairment. 3.Hepatic Function Impairment |
| Pregnancy Related Information |
| Contraindicated |
| Old Age Related Information |
| Use with caution |
| Breast Feeding Related Information |
| Use with caution |
| Children Related Information |
| Use with caution |
| Indications for Arformoterol tartrate |
| Broncho spasm in chronic obstructive pulmonary disease (COPD). |
| Interactions for Arformoterol tartrate |
| 1.Adrenergic drugs:Arformoterol sympathomimetic effects may be potentiated. Avoid concurrent use. 2.Beta-blockers :Effects of both agents may be inhibited. Do not normally treat patients with COPD with beta-blockers. However, under certain circumstances (eg, prophylaxis after MI), there may be no acceptable alternatives. In this instance, cardioselective beta-blockers could be considered; administer them with caution. 3.MAOIs, drugs known to prolong the QTc interval, tricyclic antidepressants:Arformoterol may potentiate these agents, increasing the risk of cardiac arrhythmias. Use with extreme caution. 4.Methylxanthines , steroids:May potentiate the hypokalemic effect of arformoterol. Monitor the clinical response and adjust treatment as needed. 5.Nonpotassium-sparing diuretics (eg, loop or thiazide diuretics) :ECG changes and/or hypokalemia may be worsened by arformoterol. Use with caution and closely monitor the clinical response. |
| Typical Dosage for Arformoterol tartrate |
| Inhalation 15 mcg twice daily (morning and evening) by nebulization (max, 30 mcg/day). |
| Schedule of Arformoterol tartrate |
| N/A |
| Storage Requirements for Arformoterol tartrate |
| Store in the protective foil pouch between 36? and 46?F. Protect from light and excessive heat. |
| Effects of Missed Dosage of Arformoterol tartrate |
| N/A |
| Effects of Overdose of Arformoterol tartrate |
| Contact immediate medical attention Signs and symptoms may include angina, hypertension or hypotension, tachycardia, with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose. |